FATE THERAPEUTICS INC Operating Lease Cost
FATE THERAPEUTICS INC (FATE) reported Operating Lease Cost of $15.03 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- FATE THERAPEUTICS INC operating lease, cost for the quarter ending 2024-03-31 was $4.11M, a 4.50% increase year-over-year.
- FATE THERAPEUTICS INC operating lease, cost for the quarter ending 2023-12-31 was $7.01M, a 41.41% increase year-over-year.
- FATE THERAPEUTICS INC operating lease, cost for the quarter ending 2023-09-30 was $3.92M, a 7.37% decline year-over-year.
- FATE THERAPEUTICS INC operating lease, cost for the quarter ending 2023-06-30 was $3.86M, a 15.06% decline year-over-year.
- FATE THERAPEUTICS INC operating lease, cost for fiscal 2025 was $15.03M, a 8.74% decline from fiscal 2024.
- FATE THERAPEUTICS INC operating lease, cost for fiscal 2024 was $16.47M, a 6.89% increase from fiscal 2023.
- FATE THERAPEUTICS INC operating lease, cost for fiscal 2023 was $15.41M, a 12.57% decline from fiscal 2022.
- FATE THERAPEUTICS INC operating lease, cost for fiscal 2022 was $17.62M, a 3.59% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $15.03M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $16.47M 10-K · filed 2026-02-26 | |||
| 2024-03-31 | $4.11M 10-Q · filed 2024-05-09 | $11.12M derived: sum of 2 quarters · filed 2025-03-05 | $15.04M derived: sum of 3 quarters · filed 2025-03-05 | $18.90M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-12-31 | $7.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $10.94M derived: sum of 2 quarters · filed 2025-03-05 | $14.80M derived: sum of 3 quarters · filed 2025-03-05 | $15.41M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.92M 10-Q · filed 2023-11-08 | $7.78M derived: sum of 2 quarters · filed 2023-11-08 | $8.39M 10-Q · filed 2023-11-08 | $16.67M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $3.86M 10-Q · filed 2023-08-08 | $7.68M 10-Q · filed 2023-08-08 | $12.75M derived: sum of 3 quarters · filed 2024-05-09 | $16.98M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $3.93M 10-Q · filed 2024-05-09 | $8.89M derived: sum of 2 quarters · filed 2024-05-09 | $13.13M derived: sum of 3 quarters · filed 2024-05-09 | $17.67M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $4.96M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $9.20M derived: sum of 2 quarters · filed 2024-02-26 | $13.74M derived: sum of 3 quarters · filed 2024-02-26 | $17.62M 10-K · filed 2024-02-26 |
| 2022-09-30 | $4.24M 10-Q · filed 2023-11-08 | $8.78M derived: sum of 2 quarters · filed 2023-11-08 | $12.66M 10-Q · filed 2023-11-08 | $18.49M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | $4.54M 10-Q · filed 2023-08-08 | $8.97M 10-Q · filed 2023-08-08 | $14.25M derived: sum of 3 quarters · filed 2023-08-08 | $18.32M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $4.43M 10-Q · filed 2023-05-03 | $9.71M derived: sum of 2 quarters · filed 2023-05-03 | $13.78M derived: sum of 3 quarters · filed 2023-05-03 | $17.67M derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $9.34M derived: sum of 2 quarters · filed 2023-02-28 | $13.24M derived: sum of 3 quarters · filed 2023-02-28 | $17.01M 10-K · filed 2023-02-28 |
| 2021-09-30 | $4.07M 10-Q · filed 2022-11-03 | $7.96M derived: sum of 2 quarters · filed 2022-11-03 | $11.74M 10-Q · filed 2022-11-03 | $15.47M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $3.90M 10-Q · filed 2022-08-03 | $7.67M 10-Q · filed 2022-08-03 | $11.41M derived: sum of 3 quarters · filed 2023-02-28 | $15.05M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $3.77M 10-Q · filed 2022-05-04 | $7.51M derived: sum of 2 quarters · filed 2023-02-28 | $11.16M derived: sum of 3 quarters · filed 2023-02-28 | $14.54M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $7.39M derived: sum of 2 quarters · filed 2023-02-28 | $10.77M derived: sum of 3 quarters · filed 2023-02-28 | $14.32M 10-K · filed 2023-02-28 |
| 2020-09-30 | $3.65M 10-Q · filed 2021-11-04 | $7.03M derived: sum of 2 quarters · filed 2021-11-04 | $10.58M 10-Q · filed 2021-11-04 | $12.11M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $3.39M 10-Q · filed 2021-08-04 | $6.93M 10-Q · filed 2021-08-04 | $8.47M derived: sum of 3 quarters · filed 2022-02-28 | $10.00M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $3.55M 10-Q · filed 2021-05-05 | $5.08M derived: sum of 2 quarters · filed 2022-02-28 | $6.61M derived: sum of 3 quarters · filed 2022-02-28 | $8.13M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $3.07M derived: sum of 2 quarters · filed 2022-02-28 | $4.58M derived: sum of 3 quarters · filed 2022-02-28 | $6.11M 10-K · filed 2022-02-28 |
| 2019-09-30 | $1.53M 10-Q · filed 2020-11-05 | $3.05M derived: sum of 2 quarters · filed 2020-11-05 | $4.58M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.51M 10-Q · filed 2020-08-05 | $3.04M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.50M 10-Q · filed 2019-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |